Technology evaluation: ISIS-113715, Isis.
Copyright policy )Technology evaluation: ISIS-113715, Isis.
Isis is developing ISIS-113715, an antisense inhibitor of the PTP1B gene, for the potential treatment of type 2 diabetes and obesity. ISIS-113715 is undergoing phase II clinical trials.
- Abbott (United States) United States
Male, Mice, Knockout, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Oligoribonucleotides, Clinical Trials, Phase I as Topic, Patents as Topic, Mice, Clinical Trials, Phase II as Topic, Diabetes Mellitus, Type 2, Animals, Humans, Female, Protein Tyrosine Phosphatases, Oligoribonucleotides, Antisense
Male, Mice, Knockout, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Oligoribonucleotides, Clinical Trials, Phase I as Topic, Patents as Topic, Mice, Clinical Trials, Phase II as Topic, Diabetes Mellitus, Type 2, Animals, Humans, Female, Protein Tyrosine Phosphatases, Oligoribonucleotides, Antisense
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).38 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!